Bright Minds Biosciences Inc. - common stock (DRUG)
33.10
+0.71 (2.20%)
Bright Minds Biosciences Inc. is a biopharmaceutical company focused on developing innovative therapies to treat various neuropsychiatric disorders
By leveraging advanced science and extensive research, the company aims to create new treatment options that address the underlying mechanisms of these conditions, ultimately improving the quality of life for patients. Their pipeline includes compounds that target unmet medical needs while prioritizing safety and efficacy. Through a combination of clinical trials and cutting-edge technology, Bright Minds seeks to advance the field of mental health treatment and contribute to the growing landscape of psychedelic-based medicine.
Bright Minds Biosciences Inc (NASDAQDRUG) shares are trading higher again after soaring last week. The company on Monday announced a new collaboration with brain health-focused AI company Firefly Neuroscience.
Firefly Neuroscience partners with Bright Minds Biosciences to analyze positive Phase 1 data of BMB-101 using advanced AI technology, setting the stage for Phase 2 trials.
Bright Minds Biosciences reports a significant reduction in net losses for Q3 2024 while advancing its R&D programs focused on serotonergic therapies for CNS disorders.
New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian psychiatrists provide first psychedelic-assisted treatments in 50 years.
President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also contains a mandate to fund clinical trials with psychedelics for active service members.
